Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Balance Sheet
Balance Sheet Decomposition
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Balance Sheet
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
340
|
427
|
278
|
702
|
1 413
|
5 185
|
3 784
|
2 373
|
|
| Cash |
0
|
0
|
0
|
0
|
1 413
|
5 185
|
3 784
|
2 373
|
|
| Cash Equivalents |
340
|
427
|
278
|
702
|
0
|
0
|
0
|
0
|
|
| Short-Term Investments |
21
|
0
|
63
|
103
|
240
|
2 009
|
2 455
|
2 990
|
|
| Total Receivables |
211
|
207
|
272
|
728
|
2 300
|
4 005
|
3 083
|
2 113
|
|
| Accounts Receivables |
191
|
185
|
252
|
691
|
2 256
|
3 940
|
2 991
|
2 041
|
|
| Other Receivables |
20
|
22
|
21
|
37
|
44
|
66
|
92
|
72
|
|
| Inventory |
179
|
219
|
236
|
400
|
593
|
869
|
905
|
863
|
|
| Other Current Assets |
9
|
18
|
36
|
45
|
100
|
111
|
74
|
37
|
|
| Total Current Assets |
760
|
871
|
886
|
1 978
|
4 647
|
12 180
|
10 302
|
8 375
|
|
| PP&E Net |
575
|
591
|
666
|
929
|
1 812
|
2 413
|
2 883
|
3 597
|
|
| PP&E Gross |
575
|
591
|
666
|
929
|
1 812
|
2 413
|
2 883
|
3 597
|
|
| Accumulated Depreciation |
155
|
214
|
281
|
358
|
439
|
555
|
788
|
1 107
|
|
| Intangible Assets |
254
|
249
|
242
|
234
|
295
|
332
|
643
|
713
|
|
| Goodwill |
5
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
21
|
50
|
68
|
|
| Long-Term Investments |
22
|
24
|
235
|
211
|
61
|
911
|
1 432
|
1 362
|
|
| Other Long-Term Assets |
40
|
80
|
137
|
151
|
231
|
372
|
406
|
575
|
|
| Other Assets |
5
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
1 656
N/A
|
1 815
+10%
|
2 165
+19%
|
3 504
+62%
|
7 046
+101%
|
16 230
+130%
|
15 715
-3%
|
14 689
-7%
|
|
| Liabilities | |||||||||
| Accounts Payable |
87
|
74
|
85
|
113
|
193
|
317
|
300
|
420
|
|
| Accrued Liabilities |
44
|
52
|
63
|
104
|
208
|
310
|
269
|
259
|
|
| Short-Term Debt |
100
|
0
|
0
|
78
|
235
|
175
|
173
|
128
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
14
|
14
|
13
|
38
|
|
| Other Current Liabilities |
341
|
218
|
344
|
535
|
1 715
|
2 669
|
1 915
|
1 166
|
|
| Total Current Liabilities |
571
|
344
|
492
|
829
|
2 366
|
3 485
|
2 670
|
2 012
|
|
| Long-Term Debt |
118
|
21
|
21
|
0
|
37
|
121
|
128
|
175
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
17
|
0
|
0
|
|
| Minority Interest |
21
|
21
|
22
|
27
|
96
|
224
|
183
|
185
|
|
| Other Liabilities |
67
|
79
|
71
|
94
|
80
|
41
|
34
|
54
|
|
| Total Liabilities |
778
N/A
|
465
-40%
|
606
+30%
|
950
+57%
|
2 580
+172%
|
3 888
+51%
|
3 014
-22%
|
2 427
-19%
|
|
| Equity | |||||||||
| Common Stock |
361
|
390
|
390
|
434
|
607
|
906
|
1 268
|
1 265
|
|
| Retained Earnings |
495
|
788
|
997
|
1 674
|
3 413
|
7 906
|
8 250
|
7 950
|
|
| Additional Paid In Capital |
22
|
172
|
172
|
446
|
446
|
3 729
|
3 312
|
3 139
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
200
|
129
|
92
|
|
| Total Equity |
878
N/A
|
1 350
+54%
|
1 559
+15%
|
2 554
+64%
|
4 466
+75%
|
12 341
+176%
|
12 701
+3%
|
12 263
-3%
|
|
| Total Liabilities & Equity |
1 656
N/A
|
1 815
+10%
|
2 165
+19%
|
3 504
+62%
|
7 046
+101%
|
16 230
+130%
|
15 715
-3%
|
14 689
-7%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
506
|
546
|
546
|
607
|
1 232
|
1 266
|
1 266
|
1 265
|
|